The purpose of this study is to investigate advanced pancreatic cancer without KRAS mutations. This study evaluates the effect of adding an investigational medication to standard chemotherapy in patients with this condition.
This study evaluates the safety and effectiveness of the treatment. It focuses on understanding how the investigational medication works with standard chemotherapy in improving overall survival and other health outcomes.
- Who can participate: Participants must be 18 years or older with confirmed advanced pancreatic cancer without KRAS mutations and have received prior chemotherapy.
- Study details: Participants will receive either standard chemotherapy alone or with an investigational medication. A placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine, may be used for comparison.
How understandable was the trial content above?
Hard to understand
Easy to understand